Sotera Health (SHC) Stock Forecast & Price Target

Sotera Health Co is poised for robust financial growth, with expectations for adjusted EBITDA to increase at a compound annual rate of 6.7%, growing from $589 million in 2025 to $716 million by 2028, alongside a slight margin expansion from 50.8% to 51.7%. The company's targeted cross-selling strategy has begun to yield positive results, as revenue from multi-segment customers is growing faster than overall sales, driving improvements in customer satisfaction. Furthermore, adjusted gross profit is projected to grow at a 6.4% compound annual rate, expanding from $657 million in 2025 to $791 million in 2028, indicating a strong financial trajectory driven by operational efficiencies and strategic market expansions.

Sotera Health has experienced a significant decline in its adjusted EBITDA margin, decreasing from 51.7% in 2021 to 49.9% in 2024, primarily due to inflation, overstaffing, and an unfavorable mix in its Nelson Labs segment. The company has also reported a troubling performance outlook for 2025, particularly in advisory services and Nelson Labs, which is expected to see a mid-single-digit decline as a result of the loss of high-margin COVID-related testing volumes and lower productivity. Furthermore, despite previously strong organic revenue growth, recent pressures from customer supply chain challenges and inventory de-stocking have constrained the company's top-line performance, contributing to a notable underperformance compared to the S&P 500 since its IPO.